You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東吳水泥(00695.HK)擬3250萬元向控股股東收購創新藥業務
格隆匯 11-06 22:38

格隆匯 11 月 6日丨東吳水泥(00695.HK)宣佈,公司全資附屬熙華(上海)投資管理擬向賣方東方恆信資本控股集團有限公司(由公司控股股東蔣學明直接控股)收購目標公司東方恆康生命科學有限公司全部已發行股本,代價為人民幣3250萬元。

於完成後,目標公司將成為公司的一家全資附屬公司。目標公司持有蘇州恆康已發行股本的65%。蘇州恆康位於蘇州工業園區,主要從事用於癌症及自身免疫疾病的創新藥物及治療技術的研發及商業化。目標集團擁有的主要資產包括用於研究生物科技之設施及設備。蘇州恆康餘下已發行股本的35%由Wu先生持有。

公告稱,集團致力於探索新商機,並擬為集團未來發展收購具有良好未來前景的優質業務及資產。收購事項為集團提供向大健康、生物製藥領域拓展的機會,藉此可多元化集團的業務並提升股東價值。目標公司持有蘇州恆康的65%權益。蘇州恆康主要從事用於癌症及自身免疫疾病的創新藥物及治療技術的研發及商業化。

鑑於(i)生物製藥行業的創新藥物市場興起;(ii)蘇州恆康擁有一支在研發細胞療法及抗體藥物方面具備相關技術專長及豐富經驗且強大的研究團隊;及(iii)CAR-T細胞療法(蘇州恆康開展的主要臨牀前研究項目)最近的臨牀前研究結果顯示,其對腫瘤的殺傷效果明顯且無任何副作用,董事會(不包括獨立非執行董事,彼等的意見將於考慮獨立財務顧問的意見後載於將寄發予股東的通函內)認為,訂立購股協議有助於集團進軍具有顯着增長潛力及令人振奮的業務領域,亦有助於多元化本集團的業務以及提升股東價值。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account